A group of experts from more than 30 organizations, including the National Institute of Neurological Disorders and Stroke (NINDS) and the Michael J. Fox Foundation for Parkinson's Research, is calling for standardization in the field of Parkinson's disease (PD) research, according to Medscape.
This includes recommendations for the types of biomarkers researchers should identify to aid in the development of new treatments, with a shift toward focusing on those that look within the disease itself rather than just those that distinguish patients with PD from individuals with Alzheimer's disease or who are healthy.
The paper, which was published online August 15 in Science Translational Medicine, also proposes that specific research principles be followed and lists resources for helpful collaborations.
"In the biomarker field in Parkinson's disease, it's been a little bit of a 'Wild West' in everything, including how people collect and process samples," lead author, Alice Chen-Plotkin, MD, Parker Family Associate Professor in the Perelman School of Medicine, University of Pennsylvania, Philadelphia, told Medscape Medical News.
"I think that, particularly in things with a clinical application like this, you need real transparency and you need reproducibility — and the only way to get that is to work it out as a community. So we put together a recommendation to move towards standardization," said Chen-Plotkin.
Read the full story at Medscape.